Shopping Cart 0
Cart Subtotal
USD 0

Kidney Transplant Rejection - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Kidney Transplant Rejection-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection-Pipeline Review, H2 2018, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape.

Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation are bleeding, infection, blockage of the blood vessels to the new kidney, leakage of urine or blockage of urine in the ureter and initial lack of function of the new kidney. Treatment includes immunosuppressive drugs to prevent organ rejection.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Transplant Rejection-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Kidney Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Kidney Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 9, 11, 18 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Kidney Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Transplant Rejection (Immunology).

- The pipeline guide reviews pipeline therapeutics for Kidney Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Kidney Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Kidney Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Kidney Transplant Rejection (Immunology).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Kidney Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Kidney Transplant Rejection-Overview 6

Kidney Transplant Rejection-Therapeutics Development 7

Kidney Transplant Rejection-Therapeutics Assessment 16

Kidney Transplant Rejection-Companies Involved in Therapeutics Development 26

Kidney Transplant Rejection-Drug Profiles 37

Kidney Transplant Rejection-Dormant Projects 153

Kidney Transplant Rejection-Discontinued Products 156

Kidney Transplant Rejection-Product Development Milestones 157

Appendix 169


List Of Figure

List of Figures

Number of Products under Development for Kidney Transplant Rejection, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Top 10 Molecule Types, H2 2018

Number of Products by Stage and Top 10 Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Kidney Transplant Rejection, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Kidney Transplant Rejection-Pipeline by Amgen Inc, H2 2018

Kidney Transplant Rejection-Pipeline by Angion Biomedica Corp, H2 2018

Kidney Transplant Rejection-Pipeline by Astellas Pharma Inc, H2 2018

Kidney Transplant Rejection-Pipeline by Balmes Transplantation SAS, H2 2018

Kidney Transplant Rejection-Pipeline by Bioverativ Inc, H2 2018

Kidney Transplant Rejection-Pipeline by Catalyst Biosciences Inc, H2 2018

Kidney Transplant Rejection-Pipeline by CSL Ltd, H2 2018

Kidney Transplant Rejection-Pipeline by Gilead Sciences Inc, H2 2018

Kidney Transplant Rejection-Pipeline by Hansa Medical AB, H2 2018

Kidney Transplant Rejection-Pipeline by Idogen AB, H2 2018

Kidney Transplant Rejection-Pipeline by ITB-Med AB, H2 2018

Kidney Transplant Rejection-Pipeline by Johnson & Johnson, H2 2018

Kidney Transplant Rejection-Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2018

Kidney Transplant Rejection-Pipeline by Noorik Biopharmaceuticals AG, H2 2018

Kidney Transplant Rejection-Pipeline by Novartis AG, H2 2018

Kidney Transplant Rejection-Pipeline by Opsona Therapeutics Ltd, H2 2018

Kidney Transplant Rejection-Pipeline by Pharmicell Co Ltd, H2 2018

Kidney Transplant Rejection-Pipeline by Pharming Group NV, H2 2018

Kidney Transplant Rejection-Pipeline by Prolong Pharmaceuticals LLC, H2 2018

Kidney Transplant Rejection-Pipeline by Quark Pharmaceuticals Inc, H2 2018

Kidney Transplant Rejection-Pipeline by Shire Plc, H2 2018

Kidney Transplant Rejection-Pipeline by TolerogenixX GmbH, H2 2018

Kidney Transplant Rejection-Pipeline by TxCell SA, H2 2018

Kidney Transplant Rejection-Dormant Projects, H2 2018

Kidney Transplant Rejection-Dormant Projects, H2 2018 (Contd..1), H2 2018

Kidney Transplant Rejection-Dormant Projects, H2 2018 (Contd..2), H2 2018

Kidney Transplant Rejection-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Kidney Transplant Rejection Therapeutic Products under Development, Key Players in Kidney Transplant Rejection Therapeutics, Kidney Transplant Rejection Pipeline Overview, Kidney Transplant Rejection Pipeline, Kidney Transplant Rejection Pipeline Assessment


Companies

Amgen Inc

Angion Biomedica Corp

Astellas Pharma Inc

Balmes Transplantation SAS

Bioverativ Inc

Catalyst Biosciences Inc

CSL Ltd

Gilead Sciences Inc

Hansa Medical AB

Idogen AB

ITB-Med AB

Johnson & Johnson

Kyowa Hakko Kirin Co Ltd

Noorik Biopharmaceuticals AG

Novartis AG

Opsona Therapeutics Ltd

Pharmicell Co Ltd

Pharming Group NV

Prolong Pharmaceuticals LLC

Quark Pharmaceuticals Inc

Shire Plc

TolerogenixX GmbH

TxCell SA